Long-acting cabotegravir not necessarily cost-effective for PrEP

(HealthDay)—For men who have sex with men and transgender women (MSM/TGW) at very high risk for HIV (VHR), the benefits of long-acting injectable cabotegravir (CAB-LA) in terms of life expectancy do not necessarily justify ...

Oncology & Cancer

Transgender breast cancer care

The color pink has become ubiquitous with the fight against breast cancer, raising awareness for the most deadly nonskin cancer for females in the United States.


Cabotegravir bests TDF-FTC for HIV prevention in those at risk

(HealthDay)—For men who have sex with men (MSM) and transgender women, long-acting injectable cabotegravir (CAB-LA, an integrase strand-transfer inhibitor [INSTI]) is superior to tenofovir disoproxil fumarate-emtricitabine ...

page 1 from 6